The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma.

Cancers (Basel) · 2021 · PMC8750517 · PMID 35008350

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

For example, in patients receiving nivolumab within the CheckMate 040 trial, higher CD3+ or CD8+ T cells infiltrate in pre-treatment tumour samples showed a trend toward improved OS, and increased CD3+ correlated with objective response [ 15 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.